pharmaceuticals

FAS abolished agreed prices for “Bartizar” medicinal drug
The FAS Russia established that the drug manufacturer submitted false information on the prices of raw materials supplies and set an excessive euro exchange rate in its estimates
more
FAS position on compiling the list of vital and essential drugs
The FAS Russia considered a petition of “Johnson & Johnson” Ltd. on the need to re-file a proposal to include medicinal drugs in the list of vital and essential drugs for 2018
more
FAS proposals on indexing prices for the life-saving and essential medicinal drugs in the lower price segment
Due to numerous reports in mass media FAS would like to inform that in November 2015 the Federal Antimonopoly Service (FAS Russia) indeed submitted a proposal to the Government of the Russian Federation to support domestic pharmaceutical manufacturers in the part of one-time indexing of prices for the drugs included in the list of life-saving and essential medicinal drugs with the registered price for up to 50 RUB.
more
FAS will give approvals for regional mark-ups for life-saving and essential medicines
On 1 March 2016 the Federal Antimonopoly Service (FAS Russia) shall be assigned the powers to approve regional maximum wholesale and retail mark-ups to ex-works prices for life-saving and essential medicines. The Prime Minister Dmitry Medvedev signed a relevant Decree (1) on 3 February 2016.
more